Related Experiment Video
Updated: Aug 11, 2025
03:47
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
Published on: November 1, 2024
251
Eradication therapy may decrease the risk of immune thrombocytopenia after Helicobacter pylori infection: a
Mitsuhiro Koseki1, Ming-Jen Sheu2, Kang-Ting Tsai3,4
1Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
BMC Gastroenterology
|February 9, 2023
Summary
Helicobacter pylori (HP) eradication therapy may prevent immune thrombocytopenia (ITP). Patients with HP infection not receiving therapy had a higher risk of developing ITP, especially males.
Area of Science:
- Gastroenterology
- Hematology
- Infectious Diseases
Background:
- Immune thrombocytopenia (ITP) management guidelines recommend Helicobacter pylori (HP) eradication therapy (HPE).
- The preventative role of HPE in patients with HP infection for ITP development is not well-established.
Purpose of the Study:
- To investigate the association between HPE and the risk of developing ITP in adult patients with HP infection.
- To clarify the role of HPE in preventing ITP in this patient population.
Main Methods:
- A retrospective study included 1995 adult patients with HP infection from January 2016 to December 2018 at a tertiary medical center.
- Patients were divided into two groups: those who received HPE and those who did not.
- The risk of developing ITP was compared between the groups, with follow-up until December 2020.
Main Results:
- Patients without HPE had a significantly higher risk of ITP compared to those with HPE (adjusted OR 1.76; 95% CI 1.16-2.68).
- This increased risk was primarily observed in males (adjusted OR 1.70; 95% CI 1.03-2.80).
- Male sex and anemia were identified as independent predictors of ITP in patients with HP infection.
Conclusions:
- Adult patients with HP infection who did not undergo HPE had an elevated risk of developing ITP.
- HPE should be considered as a preventative measure for ITP, particularly in male patients and those with anemia.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
498
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
498
01:26Peptic Ulcer Disease IV: Management
127
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
127
01:30Peptic Ulcer Disease I: Introduction
244
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
244
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
171
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
171
01:23Gastritis III: Clinical Manifestations and Management
377
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
377
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
496
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
496